MarketCap
Facebook
X
TelegramQuarterly report 2024-Q1
added 05-09-2024
Country |
 USA |
IPO year |
2015 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
33.4 M |
Market Cap[1] |
$ 2.17 B |
EBITDA (LTM) |
$ -67.6 M |
P/E (LTM) |
- |
P/S (LTM) |
61.97 |
EPS (LTM) |
-1.07 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Grifols, S.A.
GRFS
|
$ 7.68 | - | $ 6.83 B | Nasdaq Global Select Market |  Spain |
 |
Altimmune
ALT
|
$ 3.47 | 3.74 % | $ 306 M | Nasdaq Global Market | USA |
 |
Amgen
AMGN
|
- | - | $ 188 B | Nasdaq Global Select Market,SPB | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
- | - | $ 915 M | Nasdaq Global Select Market | USA |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market |  France |
 |
Heron Therapeutics
HRTX
|
- | - | $ 130 M | Nasdaq Global Select Market,SPB | USA |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | France |
 |
Ascendis Pharma A/S
ASND
|
$ 218.0 | -1.75 % | $ 5 B | Nasdaq Global Select Market |  Danmark |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market |  Canada |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | USA |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Incyte Corporation
INCY
|
$ 90.75 | -0.03 % | $ 17.7 B | Nasdaq Global Select Market,SPB | USA |
 |
Inovio Pharmaceuticals
INO
|
$ 1.57 | -0.63 % | $ 34.8 M | Nasdaq Global Select Market | USA |
 |
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | USA |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | USA |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market |  Israel |
 |
Cullinan Management
CGEM
|
$ 12.91 | 1.33 % | $ 778 M | Nasdaq Global Select Market | USA |
 |
Atreca
BCEL
|
- | -11.76 % | $ 5.79 M | Nasdaq Global Select Market | USA |
 |
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | USA |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
Inventiva S.A.
IVA
|
$ 6.11 | 5.71 % | $ 138 M | Nasdaq Global Market | France |
 |
Calithera Biosciences
CALA
|
- | -10.95 % | $ 876 K | Nasdaq Global Select Market | USA |
 |
Cara Therapeutics
CARA
|
- | -3.03 % | $ 260 M | Nasdaq Global Market,SPB | USA |
 |
ChemoCentryx
CCXI
|
- | - | $ 3.74 B | Nasdaq Global Select Market,SPB | USA |
 |
Bellerophon Therapeutics
BLPH
|
- | -74.18 % | $ 955 K | Nasdaq Capital Market | USA |
 |
Checkpoint Therapeutics
CKPT
|
- | - | $ 169 M | Nasdaq Capital Market | USA |
 |
Clovis Oncology
CLVS
|
- | -7.23 % | $ 13 M | Nasdaq Global Select Market | USA |
 |
KalVista Pharmaceuticals
KALV
|
$ 16.73 | -1.59 % | $ 831 M | Nasdaq Global Select Market | Britain |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
Denali Therapeutics
DNLI
|
$ 21.04 | 4.31 % | $ 3.46 B | Nasdaq Global Select Market,SPB | USA |
 |
Kamada Ltd.
KMDA
|
$ 8.27 | 0.24 % | $ 260 M | Nasdaq Global Select Market | Israel |
 |
Karyopharm Therapeutics
KPTI
|
$ 6.93 | -9.17 % | $ 845 K | Nasdaq Global Select Market | USA |
 |
Keros Therapeutics
KROS
|
$ 11.17 | 1.92 % | $ 416 M | Nasdaq Global Select Market | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 4.3 | 1.37 % | $ 714 M | Nasdaq Global Select Market | Canada |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.